Literature DB >> 8661548

Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT.

E M Loyer1, C L David, R A Dubrow, D B Evans, C Charnsangavej.   

Abstract

We defined computed tomographic (CT) criteria of vascular involvement by pancreatic carcinoma and used these criteria to assess vascular involvement in 56 patients with pancreatic adenocarcinoma. CT of the pancreas was performed at 1.5-mm section thickness and 5-mm section intervals during a bolus phase of intravenous contrast enhancement. The type of vascular involvement was correlated with surgical and pathologic findings. When there was fat-plane (type A) or normal pancreatic parenchyma (type B) separating the tumor from adjacent vessels, the tumor could be resected without venous resection in 21 of 22 patients (95%). When the tumor was inseparable from the vessels but the points of contact formed a convexity against the vessel (type C), CT was not reliable in predicting whether or not the tumor was fixed against the vessel. When the tumor was partially encircling (type D) the vessel, the tumor was fixed against the vessels in most cases. The resectable rate was 47%, but resection would also require venous resection. When the tumor was completely encircling (type E) or occluding (type F) the vessel, all tumors were not resectable with a negative margin. Thin-section CT with bolus intravenous contrast enhancement improved the ability to assess vascular involvement in pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8661548     DOI: 10.1007/s002619900046

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  36 in total

1.  An Untapped Resource: Left Renal Vein Interposition Graft for Portal Vein Reconstruction During Pancreaticoduodenectomy.

Authors:  Thuy B Tran; Matthew W Mell; George A Poultsides
Journal:  Dig Dis Sci       Date:  2016-01-29       Impact factor: 3.199

2.  Pancreatic resection for pancreatic cancer.

Authors:  Jeannine Bachmann; Christoph W Michalski; Marc E Martignoni; Markus W Büchler; Helmut Friess
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

3.  The role of chemoradiation therapy in locally advanced pancreatic cancer.

Authors:  Rebekah R White; Srinivas Reddy; Douglas S Tyler
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

4.  Pancreaticoduodenectomy with vascular resection for local advanced pancreatic head cancer: a single center retrospective study.

Authors:  Chunyou Wang; Heshui Wu; Jiongxin Xiong; Feng Zhou; Jing Tao; Tao Liu; Gang Zhao; Shanmiao Gou
Journal:  J Gastrointest Surg       Date:  2008-08-06       Impact factor: 3.452

5.  Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability.

Authors:  Vyacheslav I Egorov; Roman V Petrov; Elena N Solodinina; Gregory G Karmazanovsky; Natalia S Starostina; Natalia A Kuruschkina
Journal:  World J Gastrointest Surg       Date:  2013-04-27

6.  Predicting distant metastasis in patients with suspected pancreatic and periampullary tumors for selective use of staging laparoscopy.

Authors:  Annelie Slaar; Wietse J Eshuis; Niels A van der Gaag; C Yung Nio; Olivier R C Busch; Thomas M van Gulik; Johannes B Reitsma; Dirk J Gouma
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

7.  Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.

Authors:  Hop S Tran Cao; Alpana Balachandran; Huamin Wang; Graciela M Nogueras-González; Christina E Bailey; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans; Gauri Varadhachary; Christopher H Crane; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2013-10-16       Impact factor: 3.452

8.  Management of pancreatic cancer: current status and future directions.

Authors:  H Ramesh
Journal:  Indian J Surg       Date:  2010-11-16       Impact factor: 0.656

Review 9.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

10.  Surgical resectability of pancreatic adenocarcinoma: CTA.

Authors:  Jimmie C Wong; Steven Raman
Journal:  Abdom Imaging       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.